Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Mmmm…… delicious, cultured meat

In 2013 the first cultured meat burger was a success. You take some tissue from livestock, purify the cells, give them broth to grow on in the lab…


Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


Become MSc in Bioinformatics!

Next year, it will be possible to obtain an MSc in Bioinformatics at Ghent University. It is a new interdisciplinary education that joins the forc…

POPULAR TAGS

Hay fever medicine to treat IBS

Written by DS on in the category news with the tags .


KU Leuven researchers have traced the cause of abdominal pain in patients with irritable bowel syndrome (IBS). They also found out which compound could reduce or eliminate pain. It is the same substance as is in an existing medicine for hay fever.

IBS patients have intestines that are exceptionally sensitive, similar to a skin that is very sensitive to sunburn. Thus far, the origin of the hypersensitivity remained unknown. Researchers knew that the intestines of patients with IBS contain large amounts of the substance, histamine, but a concrete link with the hypersensitivity was not established yet.

The team of Professor and gastroenterologist Guy Boeckxstaens could now demonstrate that histamine has an effect on the pain receptor TRPV1. Histamine acts on the histamine-1 receptor, which is located on nerves that activate TRPV1. Large amounts of histamine provide an overstimulation of TRPV1. That explains the pain experienced by patients with IBS.

Based on these findings, the researchers looked for a solution to the problem. They found a substance that blocks the histamine-1 receptor on the nerve, so that the sensitivity of TRPV1 is no longer increased. This substance is ebastine, a substance that is already used in hay fever medication. Patients who were treated for twelve weeks with ebastine had significantly less abdominal pain compared with patients in the control group. In a follow-up study, the effect of ebastine will be tested on two hundred IBS patients.

Irritable bowel syndrome is a condition that affects ten to fifteen percent of the population. The present treatment is aimed at the normalization of bowel movements, but it cannot reduce or eliminate the pain. The results of this study may change that.

Read more about: .

RELATED ARTICLES
Mmmm…… delicious, cultured meat

In 2013 the first cultured meat burger was a success. You take some tissue from livestock, purify the cells, give them broth to grow on in the lab…


Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


Become MSc in Bioinformatics!

Next year, it will be possible to obtain an MSc in Bioinformatics at Ghent University. It is a new interdisciplinary education that joins the forc…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven Turnstone XpandInnovation V-Bio Ventures Itera Life Science GSK Biowin Janssen Flanders.bio UGent

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.